© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 19, 2016
As the annual ECTRIMS conference in London wound down there was definitely a sense of optimism that there would be more good news to come before the group meets next October in Paris.
When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.
September 17, 2016
One of the late breaking studies at ECTRIMS 2016 looked at how 25OH vitamin D (25OHVitD) and smoking influences disability in patients with MS.
Researchers have evaluated siponimod's efficacy in treating secondary progressive multiple sclerosis (SPMS) in a phase 3 trial.
At the moment the best way to get a diagnosis of multiple sclerosis is through a brain scan. A team in Tennessee is working to improve that with a blood test that could find the condition sooner allowing for treatment to begin faster.
As the leading minds in the field of multiple sclerosis came together in London for the annual ECTRIMS conference the end of the conference brought a considerable amount of excitement in everything from the relapsing form to progressive forms.
As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including lemtrada.
Previous research has shown that prolonged-release fampridine (PR-FAM) can help walking ability in patients with multiple sclerosis (MS), however, itâ€™s unclear whether those findings are clinically significant.
September 16, 2016
Are patients worse off if they are diagnosed with multiple sclerosis at a younger age? Thatâ€™s what Italian researchers aimed to make more clear at ECTRIMS 2016.
While neurologists may be able to successfully diagnose progressive multifocal leukoencephalopathy it may take a more specialized health care professional to effectively treat the condition.
Karan Lal, DO, MS, FAAD: Eczema Awareness Month and FDA Approval of Dupilumab
High Melanoma Incidence Associated with Diagnostic Scrutiny Rather Than UV Exposure
Robert Cionni, MD: Innovations in Drug Delivery for Glaucoma Treatment